Konstantinos N Lazaridis

List of Publications by Year
in descending order

114 papers	7,640 citations	87843 38 h-index	54882 84 g-index
122 all docs	122 docs citations	122 times ranked	10508 citing authors

#	Article	IF	Citations
1	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics, 2016, 48, 510-518.	9.4	617
2	Primary Biliary Cirrhosis Associated withHLA, IL12A,andIL12RB2Variants. New England Journal of Medicine, 2009, 360, 2544-2555.	13.9	569
3	Cholangiocarcinoma. Gastroenterology, 2005, 128, 1655-1667.	0.6	417
4	Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology, 2013, 145, 521-536.	0.6	359
5	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 1161-1170.	13.9	358
6	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
7	Ursodeoxycholic acid â€˜mechanisms of action and clinical use in hepatobiliary disordersâ€™. Journal of Hepatology, 2001, 35, 134-146.	1.8	354
8	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
9	The cholangiopathies: Disorders of biliary epithelia. Gastroenterology, 2004, 127, 1565-1577.	0.6	326
10	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. PLoS Genetics, 2014, 10, e1004135.	1.5	292
11	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nature Communications, 2015, 6, 8019.	5.8	245
12	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
13	The Cholangiopathies. Mayo Clinic Proceedings, 2015, 90, 791-800.	1.4	167
14	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human Molecular Genetics, 2012, 21, 5209-5221.	1.4	139
15	A predictive index for health status using species-level gut microbiome profiling. Nature Communications, 2020, 11, 4635.	5.8	129
16	The Genetics of Complex Cholestatic Disorders. Gastroenterology, 2013, 144, 1357-1374.	0.6	126
17	Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology, 2007, 46, 785-792.	3.6	125
18	Primary Sclerosing Cholangitis and Cholangiocarcinoma. Seminars in Liver Disease, 2006, 26, 042-051.	1.8	123

#	Article	IF	Citations
19	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology, 2020, 71, 214-224.	3.6	90
20	Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. American Journal of Gastroenterology, 2016, 111, 705-711.	0.2	88
21	Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget, 2016, 7, 54526-54536.	0.8	85
22	Performance of magnetic resonance elastography in primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1184-1190.	1.4	83
23	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. Mayo Clinic Proceedings, 2016, 91, 297-307.	1.4	83
24	Environmental Factors in Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 265-272.	1.8	64
25	Primary Biliary Cirrhosis Is Associated With a Genetic Variant in the 3â€² Flanking Region of the CTLA4 Gene. Gastroenterology, 2008, 135, 1200-1206.	0.6	62
26	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
27	Genome-Wide Association Studies in Primary Biliary Cirrhosis. Seminars in Liver Disease, 2015, 35, 392-401.	1.8	59
28	Clinical Epidemiology of Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, 494-500.	1.1	58
29	Implementing individualized medicine into the medical practice. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 15-23.	0.7	58
30	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	0.8	55
31	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
32	Biliary Multifocal Chromosomal Polysomy and Cholangiocarcinoma in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 299-309.	0.2	51
33	A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 980-990.	1.9	50
34	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 2500-2502.	13.9	48
35	Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology, 2007, 47, 563-570.	3.6	44
36	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42

#	Article	IF	Citations
37	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
38	Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 143, 879-888.	0.4	40
39	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology, 2021, 74, 281-295.	3.6	40
40	Questionnaire based assessment of risk factors for primary biliary cirrhosis. Digestive and Liver Disease, 2013, 45, 589-594.	0.4	38
41	Reduced Coffee Consumption Among Individuals With Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1562-1568.	2.4	38
42	Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: Evidence for a gene-gene interaction. Hepatology, 2010, 52, 223-229.	3.6	36
43	Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. Journal of Gastroenterology, 2014, 49, 1414-1420.	2.3	35
44	Primary biliary cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 647-654.	1.0	32
45	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Scientific Reports, 2016, 6, 25.	1.6	32
46	Update on the genetics and genomics of PBC. Journal of Autoimmunity, 2010, 35, 181-187.	3.0	31
47	A scalable workflow to characterize the human exposome. Nature Communications, 2021, 12, 5575.	5.8	31
48	Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Molecular Genetics & Genomic Medicine, 2017, 5, 269-279.	0.6	30
49	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1576-1583.e1.	2.4	30
50	Genomics and complex liver disease: Challenges and opportunities. Hepatology, 2006, 44, 1380-1390.	3.6	28
51	Kinase Genotype Analysis of Gastric Gastrointestinal Stromal Tumor Cytology Samples Using Targeted Next-Generation Sequencing. Clinical Gastroenterology and Hepatology, 2015, 13, 202-206.	2.4	28
52	Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis. International Journal of Molecular Sciences, 2018, 19, 3188.	1.8	28
53	Implementation of preemptive DNA sequenceâ€“based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genetics in Medicine, 2022, 24, 1062-1072.	1.1	28
54	Characterization of Endoscopic Ultrasound Fine-Needle Aspiration Cytology by Targeted Next-Generation Sequencing and Theranostic Potential. Clinical Gastroenterology and Hepatology, 2015, 13, 37-41.	2.4	27

#	Article	IF	Citations
55	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2017, 37, 159-174.	1.8	26
56	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1868-1881.	3.6	25
57	Impact of integrated translational research on clinical exome sequencing. Genetics in Medicine, 2021, 23, 498-507.	1.1	24
58	Genetics and Genomics of Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 349-365.	1.0	23
59	Low incidence of primary biliary cirrhosis (<scp>PBC</scp>) in the firstâ€degree relatives of <scp>PBC</scp> probands after 8 years of followâ€up. Liver International, 2016, 36, 1378-1382.	1.9	22
60	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. Journal of Gastroenterology, 2020, 55, 523-532.	2.3	22
61	Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver International, 2011, 31, 785-791.	1.9	21
62	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings, 2019, 94, 1753-1768.	1.4	21
63	Common Genetic Variation and Haplotypes of the Anion Exchanger SLC4A2 in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2009, 104, 1406-1411.	0.2	20
64	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	1.4	20
65	Variations in primary sclerosing cholangitis across the age spectrum. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1763-1768.	1.4	18
66	Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases. Hepatology, 2020, 71, 352-362.	3.6	18
67	American Gastroenterological Association Future Trends Committee Report: The Application of Genomic and Proteomic Technologies to Digestive Disease Diagnosis and Treatment and Their Likely Impact on Gastroenterology Clinical Practice. Gastroenterology, 2005, 129, 1720-1752.	0.6	17
68	Novel de novo heterozygous FGFR1 mutation in two siblings with Hartsfield syndrome: A case of gonadal mosaicism. American Journal of Medical Genetics, Part A, 2014, 164, 2356-2359.	0.7	17
69	The prevalence of diseases caused by lysosome-related genes in a cohort of undiagnosed patients. Molecular Genetics and Metabolism Reports, 2017, 13, 46-51.	0.4	17
70	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. Mayo Clinic Proceedings, 2014, 89, 718-721.	1.4	15
71	Emerging pharmacologic therapies for primary sclerosing cholangitis. Current Opinion in Gastroenterology, 2017, 33, 149-157.	1.0	14
72	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget, 2017, 8, 26245-26255.	0.8	14

#	Article	IF	Citations
73	Sclerosing Cholangitis Epidemiology and Etiology. Journal of Gastrointestinal Surgery, 2008, 12, 417-419.	0.9	13
74	PNPLA3 Association with Alcoholic Liver Disease in a Cohort of Heavy Drinkers. Alcohol and Alcoholism, 2018, 53, 357-360.	0.9	13
75	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. Scientific Reports, 2020, 10, 12584.	1.6	13
76	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	1.0	13
77	Nine-gene pharmacogenomics profile service: The Mayo Clinic experience. Pharmacogenomics Journal, 2021, , .	0.9	13
78	Applying Genomics to the Study of Complex Disease. Seminars in Liver Disease, 2007, 27, 003-012.	1.8	12
79	Emerging genes associated with the progression of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 807-811.	3.6	12
80	Improving Therapeutic Odyssey: Preemptive Pharmacogenomics Utility in Patient Care. Clinical Pharmacology and Therapeutics, 2017, 101, 39-41.	2.3	12
81	Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation. Hepatology Communications, 2022, 6, 345-360.	2.0	12
82	Highâ€Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. Hepatology Communications, 2022, 6, 965-979.	2.0	11
83	Clinical characteristics and platelet phenotype in a family withRUNX1mutated thrombocytopenia. Leukemia and Lymphoma, 2017, 58, 1963-1967.	0.6	10
84	Environmental risk factors are associated with autoimmune hepatitis. Liver International, 2021, 41, 2396-2403.	1.9	10
85	Individualized Medicine in Gastroenterology and Hepatology. Mayo Clinic Proceedings, 2017, 92, 810-825.	1.4	10
86	Association between variants in inflammation and cancerâ€associated genes and risk and survival of cholangiocarcinoma. Cancer Medicine, 2015, 4, 1599-1602.	1.3	9
87	Individualized medicine comes to the liver clinic. Journal of Hepatology, 2019, 70, 1057-1059.	1.8	9
88	Genomics, genetic epidemiology, and genomic medicine. Clinical Gastroenterology and Hepatology, 2005, 3, 320-328.	2.4	8
89	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. Future Science OA, 2020, 6, FSO441.	0.9	8
90	Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential. Gastrointestinal Endoscopy, 2015, 82, 550-556.e1.	0.5	7

#	Article	IF	Citations
91	Molecular cytology genotyping of primary and metastatic GIÂstromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent. Gastrointestinal Endoscopy, 2016, 84, 950-958.e3.	0.5	7
92	Cell-free DNA testing: future applications in gastroenterology and hepatology. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984189.	1.4	7
93	Polluting the pathogenesis of primary biliary cirrhosis. Hepatology, 2006, 43, 398-400.	3.6	6
94	Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 2007, 47, 8-10.	3.6	6
95	External validation of the United Kingdomâ€primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Hepatology Communications, 2018, 2, 676-682.	2.0	6
96	Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting. Mayo Clinic Proceedings, 2021, 96, 1407-1417.	1.4	6
97	Management of primary biliary cirrhosis: From diagnosis to end-stage disease. Current Gastroenterology Reports, 2000, 2, 94-98.	1.1	5
98	Bile formation: Do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology, 2003, 37, 218-220.	3.6	5
99	Primary biliary cholangitis, DNA, and beyond: The Relative contribution of genes. Hepatology, 2018, 68, 19-21.	3.6	5
100	Hematological malignancy manifesting as ascites. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 112-116.	1.7	4
101	Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption. Digestive Diseases and Sciences, 2022, 67, 2594-2599.	1.1	4
102	Primary biliary cirrhosis. Current Treatment Options in Gastroenterology, 1999, 2, 473-480.	0.3	3
103	Preemptive sequencing in the genomic medicine era. Expert Review of Precision Medicine and Drug Development, 2017, 2, 91-98.	0.4	3
104	<scp>PACE</scp> Forwardâ€Making Pharmacogenomics Testing Available for Realâ€Life Clinical Utility. Clinical Pharmacology and Therapeutics, 2019, 105, 42-44.	2.3	3
105	Genome-wide resolution peripheral blood methylome profiling reveals signatures for cholestatic liver disease. Epigenomics, 2020, 12, 1363-1375.	1.0	3
106	Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. BMC Gastroenterology, 2021, 21, 149.	0.8	3
107	Discovery and Opportunities With Integrative Analytics Using Multipleâ€Omics Data. Hepatology, 2021, 74, 1081-1087.	3.6	3
108	Our New Presidentâ€"Nicholas F. LaRusso, MD. Gastroenterology, 2007, 132, 2005-2011.	0.6	2

#	Article	IF	Citations
109	Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer Journal, 2020, 10, 120.	2.8	2
110	DNA methylation profile of liver tissue in end-stage cholestatic liver disease. Epigenomics, 2022, 14, 481-497.	1.0	2
111	Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 651-652.	1.8	1
112	The PSC scientific community resource: an asset for multi-omics interrogation of primary sclerosing cholangitis. BMC Gastroenterology, 2021, 21, 353.	0.8	1
113	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis. , 2022, 1, 287-295.		1
114	Ulcerative colitis and an abnormal cholangiogram. Cleveland Clinic Journal of Medicine, 2011, 78, 306-311.	0.6	0